Showing results (1-10 of 16) with videos related to
Sort By:
Pageof 2
The Journal of Clinical Psychiatry|June 11, 2004
Pathophysiology of antipsychotic drug-induced movement disordersDaniel E CaseyThe American Journal of Medicine|May 21, 2005
Metabolic issues and cardiovascular disease in patients with psychiatric disordersDaniel E CaseyCNS Spectrums|July 4, 2006
Implications of the CATIE trial on treatment: extrapyramidal symptomsDaniel E CaseyThe Journal of Clinical Psychiatry|December 17, 2004
Dyslipidemia and atypical antipsychotic drugsDaniel E CaseyJournal of Clinical Psychopharmacology|May 15, 2009
A double-blind randomized trial of mood stabilizer augmentation using lamotrigine and valproate for patients with schizophrenia who are stabilized and partially responsiveIra D Glick, Jeane Bosch, Daniel E CaseyAmerican Heart Journal|December 13, 2005
Schizophrenia and increased risks of cardiovascular diseaseCharles H Hennekens, Alissa R Hennekens, Danielle Hollar, et al.Psychopharmacology|July 4, 2008
Efficacy and safety of bifeprunox in patients with an acute exacerbation of schizophrenia: results from a randomized, double-blind, placebo-controlled, multicenter, dose-finding studyDaniel E Casey, Earl E Sands, Jens Heisterberg, et al.Journal of Pharmacological Sciences|December 4, 2003
Effect of a novel potential atypical antipsychotic drug, Y-931, in producing dystonia in cebus monkeysYasuyuki Shiigi, Jun-ichi Maeda, Hiroshi Yasumatsu, et al.The Primary Care Companion for CNS Disorders|October 30, 2012
Efficacy of adjunctive aripiprazole in major depressive disorder: a pooled response quartile analysis and the predictive value of week 2 early responseDaniel E Casey, Kimberly K Laubmeier, Sabrina Vogel Marler, et al.Pageof 2